Asthma

Reports from University Medical Center describe recent advances in asthma

Published in Medicine and Law Weekly, February 12th, 2010

"Long-acting beta(2)-agonists are an established controller medication in asthma. BI 1744 is a novel L/long-acting beta(2)-agonist with a preclinical profile that suggests 24-hour bronchodilation and bronchoprotection may be achieved," researchers in Hamilton, Canada report.

"To examine the bronchoprotective effects of single doses of BI 1744 against methacholine provocation in subjects with mild asthma. Thirty-one subjects with mild asthma were randomized to receive single doses of BI 1744 (2, 5, 10, 20 mu g) or placebo on separate days according to a double-blind, 5-way crossover design. Methacholine challenges were performed at 30 minutes and at 4, 8, 24, and 32...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2010-02-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry